 |
2 Diseases |  |
1 Trial |
|
1 Trial |  |
52 News |  |
- || neladenoson (BAY 1067197) / Bayer, capadenoson (BAY 684986) / Bayer
Clinical, Journal: Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. (Pubmed Central) - Mar 30, 2021
The failure of neladenoson to reach primary endpoints in clinical trials suggests that AR-mediated cAMP inhibition may be a poor indicator of effectiveness in chronic heart failure. This study provides additional information that can aid future screening and/or design of improved AR agonists that are safe and efficacious in treating heart failure in patients.
- | neladenoson (BAY 1067197) / Bayer, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
Journal: More Purinergic Receptors Deserve Attention as Therapeutic Targets for the Treatment of Cardiovascular Disease. (Pubmed Central) - Nov 26, 2020
The P2YR antagonists such as clopidogrel, ticagrelor, and others are the most successful class of purinergic drugs targeting platelets for the treatment of acute coronary syndrome...The partial AR agonist neladenoson and the AR agonist regadenoson have been applied in cardiovascular medicine...The present review discusses the promising purinergic drugs used in clinical studies for the treatment of cardiovascular disease. We also update experimental evidence for many other PRs that can be considered as therapeutic targets for future drug development.
- || neladenoson (BAY 1067197) / Bayer
Clinical, P2b data, Journal: Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Oct 22, 2020
P2
We also update experimental evidence for many other PRs that can be considered as therapeutic targets for future drug development. In patients with chronic HFrEF, treatment with neladenoson bialanate was not associated with dose-dependent favourable effects on cardiac structure and function, cardiac risk markers, or clinical outcome but was associated with a dose-dependent decrease in renal function.
- neladenoson (BAY 1067197) / Bayer
New P1 trial: Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight (clinicaltrials.gov) - Mar 25, 2020
P1, N=22, Terminated, Sponsor: Bayer
- neladenoson (BAY 1067197) / Bayer
New P1 trial: Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight (clinicaltrials.gov) - Mar 24, 2020
P1, N=18, Terminated, Sponsor: Bayer
- | neladenoson (BAY 1067197) / Bayer
Biomarker, Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. (Pubmed Central) - Jun 22, 2019
P2
In light of these findings, novel approaches will be needed if further development of neladenoson for the treatment of patients with HFpEF is pursued. ClinicalTrials.gov Identifier: NCT03098979.
- | neladenoson (BAY 1067197) / Bayer
Neladenoson not beneficial in #HFpEF #CardioTwitter @HFpEF https://t.co/RmgKC5FriI (Twitter) - Jun 14, 2019
- | neladenoson (BAY 1067197) / Bayer
Clinical, P2b data, Journal: Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. (Pubmed Central) - Mar 23, 2019
However, data on this class of drugs in humans are scarce, and the optimal dose of the partial adenosine A1 receptor, neladenoson bialanate, has not been defined. Here we describe the design and rationale of two randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase 2b trials, PANTHEON (HFrEF) and PANACHE (HFpEF), that will advance our understanding of the potential benefit and optimal dose of neladenoson bialanate and provide critical information for the planning of future phase 3 trials.
- | Review, Journal: Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. (Pubmed Central) - Feb 6, 2019
Myocardial energetics-based therapeutics are groundbreaking in that they utilize novel mechanisms of action to improve heart failure symptoms, without causing the adverse neurohormonal side effects associated with current guideline-based therapies. The drugs appear likely to be added to the heart failure therapy armamentarium as adjuncts to current regimens in the near future.
- |||| neladenoson (BAY 1067197) / Bayer
Trial completion: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Jun 26, 2018
P2, N=305, Completed, Sponsor: Bayer
The drugs appear likely to be added to the heart failure therapy armamentarium as adjuncts to current regimens in the near future. Active, not recruiting --> Completed
- |||| neladenoson (BAY 1067197) / Bayer
Trial completion: PANTHEON: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Jun 6, 2018
P2, N=427, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || neladenoson (BAY 1067197) / Bayer
Trial completion date: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Mar 7, 2018
P2, N=305, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial completion date: Jun 2018 --> Jun 2018
- || neladenoson (BAY 1067197) / Bayer
Trial primary completion date: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Mar 3, 2018
P2, N=305, Active, not recruiting, Sponsor: Bayer
Trial completion date: Jun 2018 --> Jun 2018 Trial primary completion date: Apr 2018 --> May 2018
- ||| neladenoson (BAY 1067197) / Bayer
Enrollment closed: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Jan 9, 2018
P2, N=288, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Apr 2018 --> May 2018 Recruiting --> Active, not recruiting
- || neladenoson (BAY 1067197) / Bayer
Trial primary completion date: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Dec 5, 2017
P2, N=288, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2018 --> Apr 2018
- ||| neladenoson (BAY 1067197) / Bayer
Enrollment closed: PANTHEON: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Dec 4, 2017
P2, N=427, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jul 2018 --> Apr 2018 Recruiting --> Active, not recruiting
- || neladenoson (BAY 1067197) / Bayer
Trial primary completion date: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Oct 15, 2017
P2, N=288, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2018 --> Jul 2018
- || neladenoson (BAY 1067197) / Bayer
Trial primary completion date: PANTHEON: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Sep 6, 2017
P2, N=384, Recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2018 --> Jul 2018 Trial primary completion date: Jul 2018 --> Apr 2018
- | neladenoson (BAY 1067197) / Bayer
Journal: Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients with Chronic Heart Failure. (Pubmed Central) - Aug 17, 2017
Treatment of HFrEF patients with the novel partial adenosine A1 agonist neladenoson bialanate appeared to be safe in two small pilot studies, and no atrioventricular conduction disorders or neurological side effects were observed. No significant early changes in cardiac function were detected.
- |||| neladenoson (BAY 1067197) / Bayer
Enrollment open: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - May 19, 2017
P2, N=288, Recruiting, Sponsor: Bayer
No significant early changes in cardiac function were detected. Not yet recruiting --> Recruiting
- ||||| neladenoson (BAY 1067197) / Bayer
New P2 trial: PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Apr 4, 2017
P2, N=288, Not yet recruiting, Sponsor: Bayer
- |||| neladenoson (BAY 1067197) / Bayer
Enrollment open: PANTHEON: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Mar 3, 2017
P2, N=384, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| neladenoson (BAY 1067197) / Bayer
New P2 trial: PANTHEON: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Dec 14, 2016
P2, N=384, Not yet recruiting, Sponsor: Bayer
- neladenoson (BAY 1067197) / Bayer
Phase classification: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Jun 15, 2015
P2, N=11, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Phase classification: P1/2 --> P2
- | neladenoson (BAY 1067197) / Bayer
Trial completion: PARSiFAL: Multiple Dose Study in Heart Failure of BAY 1067197 (clinicaltrials.gov) - Apr 9, 2015
P2, N=31, Completed, Sponsor: Bayer
Phase classification: P1/2 --> P2 Active, not recruiting --> Completed
- | neladenoson (BAY 1067197) / Bayer
Enrollment closed: PARSiFAL: Multiple Dose Study in Heart Failure of BAY 1067197 (clinicaltrials.gov) - Dec 29, 2014
P2, N=31, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | neladenoson (BAY 1067197) / Bayer
Enrollment closed: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Dec 9, 2014
P1/2, N=11, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- | neladenoson (BAY 1067197) / Bayer
Trial completion: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=11, Completed, Sponsor: Bayer
Completed --> Active, not recruiting Active, not recruiting --> Completed
- neladenoson (BAY 1067197) / Bayer
Enrollment closed: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Aug 15, 2014
P1/2, N=10, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- neladenoson (BAY 1067197) / Bayer
Trial completion date: PARSiFAL: Multiple Dose Study in Heart Failure of BAY 1067197 (clinicaltrials.gov) - May 7, 2014
P2, N=32, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial completion date: Sep 2014 --> Nov 2014
- | neladenoson (BAY 1067197) / Bayer
Enrollment open: PARSiFAL: Multiple Dose Study in Heart Failure of BAY 1067197 (clinicaltrials.gov) - Feb 5, 2014
P2, N=32, Recruiting, Sponsor: Bayer
Trial completion date: Sep 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- | neladenoson (BAY 1067197) / Bayer
New P2 trial: PARSiFAL: Multiple Dose Study in Heart Failure of BAY 1067197 (clinicaltrials.gov) - Jan 16, 2014
P2, N=32, Recruiting, Sponsor: Bayer
- neladenoson (BAY 1067197) / Bayer
Enrollment open: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Dec 12, 2013
P1/2, N=10, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- neladenoson (BAY 1067197) / Bayer
New P1/2 trial: Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker (clinicaltrials.gov) - Sep 16, 2013
P1/2, N=10, Recruiting, Sponsor: Bayer